Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. Available from: / ViewArticle.aspx?ArticleId=21169

In this issue

Home Eurosurveillance Edition  2010: Volume 15/ Issue 48 Article 2
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 15, Issue 48, 02 December 2010
Rapid communications
HIV and AIDS in the European Union, 2009
  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Citation style for this article: Likatavicius G, Van de Laar MJ. HIV and AIDS in the European Union, 2009. Euro Surveill. 2010;15(48):pii=19737. Available online:
Date of submission: 29 November 2010

In 2009, 28 European Union and European Economic Area (EU/EEA) countries reported 25,917 newly diagnosed cases of human immunodeficiency virus (HIV). Sex among men who have sex with men was the most common transmission mode (35%) followed by heterosexual contact (24%). Overall, the number of HIV cases in 2009 increased while the number of reported acquired immunodeficiency syndrome (AIDS) diagnoses continued to decline. It is of concern that a high proportion of the patients with known CD4 cells count at the time of HIV diagnosis had a CD4 cell count below 350cells/µl suggesting no timely access to treatment and care.

Human immunodeficiency virus (HIV) cases in the European Union and European Economic Area (EU/EEA), 2009
In the EU/EEA, 25,917 people were newly diagnosed with HIV in 2009, reported by 28 countries, a rate of 5.7 per 100,000 population. Data was not reported from Austria or Liechtenstein. The overall rate for men was 8.3 per 100,000 male population and 3.2 for women. The highest rates of new HIV diagnoses were reported by Estonia (30.7), Latvia (12.2), the United Kingdom (UK) (10.7) and Belgium (10.3). The lowest rates (<1.0) were reported by Romania and Slovakia. Twelve per cent of new HIV diagnoses were reported in 15–24 year-old individuals and 28% were female. Sex among men who have sex with men (MSM) is the predominant reported mode of transmission in EU/EEA, accounting for 35% of the HIV diagnoses, followed by heterosexual contact (24%) when cases from countries with generalised HIV epidemics are excluded. Five per cent of HIV cases were reported among intravenous drug users (IDU). Transmission mode was unknown for 20.3% of the cases. The highest proportion of cases classified as heterosexually transmitted and originating from countries with generalised epidemics, was observed in Norway (70%), Sweden (69%), Ireland (62%) and Belgium (60%).

Trends in HIV cases in the EU/EEA
Among the 28 EU/EEA countries that have consistently reported HIV data since 2004, the rate of HIV diagnoses per 100,000 population has been relatively stable, ranging from 6.5 in 2004 to 5.7 in 2009. In recent years, more than 25,000 HIV diagnoses were reported each year, resulting in a cumulative total number of nearly 350,000 diagnoses reported since the beginning of the epidemic (Figure 1). Since 2004, the proportion of newly HIV diagnosed women decreased from 36% to 28% in 2009. HIV diagnoses have tripled in Bulgaria, Iceland and Slovakia and doubled in Hungary and Slovenia. HIV diagnoses have decreased by more than 20% in Denmark, Estonia, Italy, Luxembourg and Romania.

Figure 1. Number of diagnosed and reported HIV infections EU/EEA,1984–2009

Since 2004, 26 EU/EEA countries have consistently reported data on transmission mode (Estonia and Poland were excluded due to inconsistent reporting). The number of new HIV diagnoses reported as heterosexually acquired decreased by 24% from 13,148 cases to 9,975 cases. The proportion of heterosexually acquired HIV diagnoses from countries with a generalised epidemic, varied from 52% in 2004 to 38% in 2009. In the same period, the number of cases among MSM increased by 24% in, from 7,263 cases to 8,974 cases and declined among IDU by 40% from 1,952 cases to 1,171 cases. The number of cases for which the transmission category was unknown increased by 40% (Figure 2). There are reporting delays for a number of countries which overall limits the ability to interpret the trends in recent years.

Figure 2. HIV diagnoses by transmission group and origin in EU/EEA countriesa, 2004–2009*

In 2009, a total of 4,650 cases of AIDS diagnoses were reported in 27 EU/EEA countries (no data from Austria, Liechtenstein, Sweden), representing a rate of 1.0 cases per 100,000 population. The highest rates were reported by Latvia (4.3), Estonia (2.8), Portugal (2.8), and Spain (2.3). In the EU/EEA, a decline was observed from 9,012 in 2004 to 4,650 in 2009 in all but four countries of the 27 countries reporting AIDS diagnoses consistently. An increase in AIDS diagnoses was reported only in Bulgaria from 22 cases to 30 cases (36%), Estonia 29 cases to 38 cases (31%), Latvia 89 cases to 96 cases (8%) and Lithuania 21 cases to 37 cases (76%).

Proportion of late presenters
Late presenters are defined as patients with a CD4 cell count below 350 cells/µl at time of HIV diagnosis [1]. Data on CD4 cell counts at the time of diagnosis were available for cases in 18 countries, ranging from 1.2% in Bulgaria to 87% in Spain. For 11 countries, CD4 count information was available for more than 50% of the cases (Table). Half of these were reported as late presenters, also taking into account possible reporting bias for more advanced HIV diagnoses. A slightly higher proportion of female cases (54.4%) were reported as late presenters compared with male cases (49.6%), with high heterogeneity among females across countries ranging from 33% in Cyprus and Luxembourg to 68% in Denmark. Among males, the proportion of late presenters ranged from 20% in Luxembourg to 60% in Denmark.

Table. Proportion of CD4 cell counts reported for all HIV cases diagnosed in 2009, CD4 cell counts <350 among all reported, and CD4 cell proportion and counts <350 by transmission mode and reporting country, 11 European Union Member Statesa, 2009

Among new diagnoses acquired heterosexually the proportion of late presenters ranged from 20% in Luxembourg to 67% in Slovakia, while seven countries reported more than 50% of the newly diagnosed cases as late presenters (Table). For MSM, the proportion of late presenters varied from 25% in Luxembourg to 50% in Slovenia (Table). Among IDU, the proportion of late presenters ranged from 49% in the UK to 60% in Denmark. All countries but Spain and the UK reported more than half of their cases with unknown risk factor as late presenters.
Figure 3 shows that among 10 222 cases with CD4 cell count reported, 51% were “late presenters”. The largest proportion of late presenters is among individuals originating from sub-Saharan Africa and southeast/eastern Asia, followed by cases from the Caribbean and Latin America. The proportion of late presenters is slightly higher in eastern Europe compared with central and western Europe. The areas are defined in the most recent ECDC/WHO HIV/AIDS surveillance report [4].
Figure 3. All cases with CD4 cell count reported, proportion of late presenters by region of origin (n=10,222)


As in previous years, the highest proportion of the total number of new HIV diagnoses in 2009 in EU/EEA countries was reported among MSM, followed by heterosexuals. For the known transmission modes, a substantial increase was reported only in MSM. Heterosexual HIV transmission continues to be frequently reported; the proportion of cases classified as heterosexually acquired in persons originating from countries with generalised epidemics is decreasing, although it is still high in several countries. Although there is an apparent decline in the number of HIV diagnoses among IDU, injecting drug use is still the predominant transmission mode in several Eastern European countries. The transmission mode for a significant proportion of cases was reported as unknown, highlighting the importance of the improvement of surveillance data to better target public health interventions. The number of AIDS cases is decreasing in most of the countries except Bulgaria and Baltic States.

It is important to obtain more rigorous HIV surveillance data to better reflect changing epidemiological conditions. Inclusion of CD4 cell count at diagnosis provides an opportunity to interpret the data in greater depth. However, the reporting of CD4 cell counts needs to be improved as it was reported only for 40% of all new HIV diagnoses in 2009. Half of those were diagnosed as late presenters’, and it appears that late presenters are more often from outside of Europe. Timely HIV diagnosis is beneficial for the patient as it decreases morbidity and mortality and reduce HIV transmission [2-3]. Many factors influence the interpretation of the data such as the stage of the epidemic in the region, migration patterns and reporting bias. However the data suggest that access to testing and treatment needs to be improved among those at risk. Recently, ECDC has launched guidance in HIV testing to support Member States in the increasing the uptake of HIV testing in Europe [4-7]

Surveillance of HIV and AIDS in Europe provides the large scale picture of the HIV epidemics within its regions and of its main characteristics and risk groups affected, which is necessary to monitor the epidemic and guide the public health response to control HIV transmission of infections. Ensuring high quality of the data is of utmost importance to follow up and achieve the objectives set up in the EU Commission communication and action plan ’Combating HIV/AIDS in the European Union and Neighbouring countries, 2009-2013’.

We would like to thank all participating countries and national institutions of the European network for HIV/AIDS surveillance as well as colleagues at ECDC for their important contributions. In particular we would like to acknowledge M Maly, M Mardarescu, C Semaille, F Cazein and V Delpech for their valuable comments and suggestions. 

At the request of the authors, the following change was made on 8 December: The text of two of the legends in Figure 2 were changed from 'Heterosexuals originating from high prevalence countries', and 'Heterosexual contact' into ''Heterosexuals originating from countries with generalised epidemic' and 'Heterosexuals originating from countries with non generalised epidemic or reporting country, respectively .


  1. Antinori A, Coenen T, Costagiola D, Dedes N et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2010 Jun 17.
  2. van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS. 2003;17(15):2227-36.
  3. Zwahlen M, Harris R, May M, Hogg R, Costagliola D and Antiretroviral Therapy Cohort Collaboration. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol. 2009;38(6):1624-33.
  4. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2009: Stockholm, European Centre for Disease Prevention and Control; 2010. Available from:
  5. European Centre for Disease Prevention and Control. ECDC Guidance HIV testing: Increasing the uptake and effectiveness in the European Union, in brief. Stockholm, European Centre for Disease Prevention and Control; 2010. Available from:
  6. European Centre for Disease Prevention and Control. ECDC Guidance HIV testing: Increasing the uptake and effectiveness in the European Union. Stockholm, European Centre for Disease Prevention and Control; 2010. Available from:
  7. European Centre for Disease Prevention and Control. Technical Report: Increasing the uptake and effectiveness in the European Union: Evidence synthesis for Guidance on HIV testing. Stockholm, European Centre for Disease Prevention and Control; 2010 Available from:


Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.